key: cord-0024609-lbew2eqy
authors: Arslan, Burak; Şemsi, Rabia; İriz, Ayşe; Sepici Dinçel, Aylin
title: The evaluation of serum brain‐derived neurotrophic factor and neurofilament light chain levels in patients with obstructive sleep apnea syndrome
date: 2021-10-20
journal: Laryngoscope Investig Otolaryngol
DOI: 10.1002/lio2.683
sha: 584f0530a1f1433ce76aace56f54e59e329e6f85
doc_id: 24609
cord_uid: lbew2eqy

OBJECTIVES: This study aimed to compare serum levels of brain‐derived neurotrophic factor (BDNF) and neurofilament light (NfL) chain in normal individuals and patients with mild and moderate‐severe obstructive sleep apnea syndrome (OSAS). METHODS: We enrolled 81 subjects referred to Otorhinolaryngology (Ear‐Nose‐Throat), Gazi University Faculty of Medicine, between 2017 and 2019. Based on the severity of OSAS, patients were divided into three groups: group 1 with mild OSAS (apnea‐hypopnea index [AHI] 5‐15; n = 26), group 2 with moderate‐severe OSAS (AHI > 15; n = 32), and group 3 with normal individuals (AHI scores < 5; n = 23). RESULTS: Serum NfL and BDNF levels were evaluated together with the clinical data for all subjects. Significant differences were seen in the oxygen desaturation index (ODI), apnea index, hypopnea index, sleep efficiency, and NfL levels (P < .05) between the three groups. In the moderate‐severe group, NfL levels showed a significant positive correlation with apnea index (P < .05, r = .389), hypopnea index (P < .05, r = .455), and ODI (P = .04; r = .362). CONCLUSIONS: Our findings clarify the pathophysiology of OSAS in cases of repetitive hypoxia and chronic neuronal damage. Based on our results, we recommend that in addition to BDNF, NfL should also be evaluated in different and larger patient cohorts.

Neurocognitive impairment is one of the important comorbidities associated with neurodegenerative diseases such as Alzheimer's and Parkinson's. It is also a major complication associated with OSAS. 8, 9 Although sleep fragmentation may cause cognitive dysfunction owing to neuronal damage, it has been shown in experimental and clinical studies that chronic intermittent hypoxia causes some structural and functional brain changes. Experimental studies using mouse models of OSAS have shown decreased neuronal excitability in mouse hippocampal neurons 10 and increased apoptosis in the cortex. 11 Additionally, increased amyloid-beta levels (AB42) were detected in the cortex of mice exposed to chronic intermittent hypoxia. All these data support that the cascade of events induced by OSAS aggravates neuronal degeneration. 12 Chronic intermittent hypoxia triggers systemic and neuronal inflammation. However, some adaptive mechanisms are initiated simultaneously to fix the damage. 5 Brain-derived neurotrophic factor (BDNF) is an essential neurotrophin that has a role in neuroplasticity, neurogenesis, neuronal development, and neuronal survival. This growth factor has been shown to play a role in mental illness, regulation of memory and sleep, and insomnia. [13] [14] [15] [16] [17] [18] Serum BDNF levels increase in various conditions related to neuronal damage, indicative of its neuroprotective role in OSAS patients in response to intermittent hypoxia. The lack of BDNF during chronic intermittent hypoxia causes both the impairment of long-term synaptic plasticity and the inability to prevent neuronal damage. 19, 20 The neurofilament light chain (NfL) is the main intermediate filament in neurons that maintain axonal stability. Whatever the cause, any axonal damage causes increased NfL levels in the cerebrospinal fluid (CSF) and serum. 21 Chronic intermittent hypoxia may also cause neuronal degeneration and NfL release over time.

Since BDNF is a protective factor that comes into play in response to chronic intermittent hypoxia, its relationship with NfL, which indicates axonal damage, helps distinguish between mild and severe OSAS patients.

This study aimed to compare serum levels of BDNF and NfL in patients with mild and moderate-severe OSAS with a group of normal controls. We also evaluated the relationship between these serum biomarkers and other clinical features such as the Epworth Sleepiness Score (ESS) and apnea-hypopnea index (AHI).

In this study, we enrolled 81 subjects referred to Otorhinolaryngology severe OSAS. Subjects were divided into three groups: group 1 with mild OSAS (AHI scores 5-15; n = 26), group 2 with moderate-severe OSAS (AHI scores > 15; n = 32), and group 3 of normal individuals (AHI scores < 5; n = 23).

All patients were interviewed to collect information on sex, age, medical history, and record anthropometric characteristics, including weight, height, and body mass index (BMI).

The exclusion criteria were (1) brain trauma and neurological disorders with cognitive dysfunction; (2) dementia and neurodevelopmental disorders; (3) current and lifetime history of any psychiatric disorders; (4) severe physical diseases including cancer, rheumatism, stroke, and epilepsy, and other diseases involving thyroid, liver, kidney, lung, cardiovascular, endocrinal, and nervous system; (5) alcoholics and drug abusers; and (6) pregnant, menstrual and breastfeeding women.

Fasting blood was collected between 07:00 and 07:30 A.M., the morning after PSG monitoring using a serum separator tube. Serum samples were prepared by centrifugation at 3200 Â g for 10 minutes at 4 C and stored at À80 C until assaying. Serum BDNF and NfL levels were measured using an enzyme-linked immunosorbent assay kit according to the manufacturer's instructions (Ray Bio Human BDNF ELISA Kit Cat: ELH-BDNF Lot: 0515200106, Abbexa abx258398

Human NfL ELISA Kit Lot: E2002668G). The absorbance was measured at 450 nm using a microplate reader to determine BDNF (ng/mL) and NfL (pg/mL) concentrations.

All patients underwent full setup overnight PSG and were allocated to the different study groups based on their AHI scores. The sleep test was performed using the Nocturnal A1 System, version 2.0 (Nox Medical ehf Katrinartuni 2 IS-105 Reykjavik, Iceland). Every sleep study was reviewed and interpreted by a qualified sleep clinician. Apnea is defined as the absence of airflow for ≥10 seconds, and hypopnea is defined as a decrease in respiratory effort with ≥4% oxygen desaturation according to American Academy of Sleep Medicine (AASM) acceptable rule 1B criteria. 22 The severity of OSAS was quantified based on the AHI, and the scores were dichotomized for descriptive statistics using a 

Our study was approved by the Ethics Review Board of the Gazi University Faculty of Medicine Ethics Committee (Approval # 573-10.09.2018). All the participants gave written informed consent.

Statistical tests were performed with SPSS software (IBM SPSS 18, statistical software). The distribution of the variables was validated by the normality test, and the differences between groups were evaluated using Kruskal-Wallis H to correct for multiple comparisons. The mean for the groups was compared using the one-way ANOVA test. Categorical variables were evaluated by the chi-square test. Correlation between clinical and biochemical data was assessed by Spearman rho correlation analysis. The relationships between age, gender, BMI, ODI, and levels of BDNF and NfL were examined using the Spearman correlation coefficient. All the tests were performed at a P < .005 significance level.

After applying the inclusion and exclusion criteria, based on the OSAS severity, we had three groups of subjects: normal (n = 23), mild (n = 26), and moderate-severe (n = 32). None of the subjects F I G U R E 1 A, Mean ± SD of serum BDNF levels in normal and OSAS groups. Serum BDNF levels show a significant difference between the two groups (P = .007) (left). B, Mean ± SD of serum NfL levels in normal and OSAS groups. Serum NfL levels show no significant difference between the two groups (P = .847) (right) (Figure 1 ).

In the moderate-severe group, apnea index and hypopnea index showed a significant positive correlation with the NfL (P < .05, r = .389 and P < .05, r = .455, respectively), but not with BDNF levels ( Figure 2 ). All three groups showed a positive linear correlation between sleep efficiency and AHI (P < .05) ( Figure 3 ).

BDNF and NfL showed no statistical significance (P > .05) (Figure 4 ).

NfL levels compared on the basis of BDNF levels, showed significant differences in the mild, and moderate-severe groups when compared to the normal group ( Figure 5 ). However, no significant relationship was seen between NfL and BDNF levels in the mild (r = À.004, P = .986), moderate-severe (r = .176, P = .335), and normal (r = À.211, P = .334) groups.

In the moderate-severe group, the ODI values showed a direct correlation with the serum NfL (P = .04; r = .362) ( Figure 6 ), but not the BDNF levels. In addition, a significant positive correlation was seen between ST 90,min , and NfL values in the mild (r = .450, P = .021) and moderate-severe (r = .378, P = .033) groups (Table 2) .

Based on the ODI, patients were divided into three groups: mild (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , moderate (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) , and severe (≥30). Patients with an ODI < 5

were graded as having no oxygen disturbance, while those with an ODI > 15 were classified as moderate-severe. These three groups showed significant differences in the NfL (P = .008) but not the BDNF 

Intermittent chronic hypoxemia is a risk factor for serious complications related to OSAS, such as neurocognitive deterioration. 23 It causes inflammation, oxidative stress, endothelial dysfunction, and increased sympathetic activation, contributing to multi-organ comorbidities. 24 Recurrent episodes of hypoxia-reoxygenation are associated with high levels of pro-inflammatory markers, including tryptophan and kynurenine. In addition, determining the kynurenine/ tryptophan ratio can provide information about the course of chronic diseases. 25 OSAS patients diagnosed at a late stage are associated with neurocognitive impairment, a well-recognized public health concern. 26 Chronic intermittent hypoxia results in neuronal and, finally, axonal damage, leading to the release of NfL first into the CSF and then blood. This is the first study to evaluate serum NfL levels in efficacy. 28 In line with these findings, we found no significant association between sleep efficiency and NfL. However, we could not evaluate the relationship between sleep depth and NfL levels. In addition, the NfL levels in the CSF were higher than the serum levels measured in our study.

BDNF has a critical role in neuroprotection and neuronal plasticity in the central and peripheral nervous systems. 19 An increase in the oxidation state of the cell leads to upregulation of cellular elements responsible for the secretion of inflammatory cytokines, and as hypoxia continues, inflammation increases, inevitably resulting in cellular apoptosis and necrosis. [31] [32] [33] [34] When occurring in the neuron, these events lead to neuronal damage, which increases as the exposure to chronic intermittent hypoxia increases. As a result, the expression of BDNF, one of the most important elements of the adaptive neuroprotective response expression, is increased. 20 In our study, since the moderate-severe group was the most exposed to a hypoxic state, it also 

Obstructive sleep apnea

Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline

Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea

Melatonin concentration as a marker of the circadian phase in patients with obstructive sleep apnoea

Protective role of brain derived neurotrophic factor (BDNF) in obstructive sleep apnea syndrome (OSAS) patients

Obstructive sleep apnea syndrome (OSAS). Review of the literature

Gender differences in symptoms related to sleep apnea in a general population and in relation to referral to sleep clinic

Neurocognitive impairment in obstructive sleep apnea

The association between obstructive sleep apnea and Alzheimer's disease: a meta-analysis perspective

Decreased neuronal excitability in hippocampal neurons of mice exposed to cyclic hypoxia

Increased oxidative stress is associated with chronic intermittent hypoxia-mediated brain cortical neuronal cell apoptosis in a mouse model of sleep apnea

Chronic intermittent hypoxia/reoxygenation facilitate amyloid-β generation in mice

Brain-derived neurotrophic factor and neuropsychiatric disorders

Brain-derived neurotrophic factor

A simple role for BDNF in learning and memory?

Neuronal plasticity and survival in mood disorders

Objective sleep duration is associated with cognitive deficits in primary insomnia: BDNF may play a role

A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep

Brain preconditioning and obstructive sleep apnea syndrome

Chronic intermittent hypoxia-induced deficits in synaptic plasticity and neurocognitive functions: a role for brainderived neurotrophic factor

Increased neurofilament light chain blood levels in neurodegenerative neurological diseases

AASM Clarifies Hypopnea Scoring Criteria

The value of oxygen desaturation index for diagnosing obstructive sleep apnea: a systematic review

Intermittent hypoxemia and OSA: implications for comorbidities

The evaluation of serum tryptophan and kynurenine levels in patients with obstructive sleep apnea syndrome

Neurocognitive effects of obstructive sleep apnea syndrome

Value of blood IFN-I levels in COVID-19 management

Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer's disease

Acute intermittent hypoxia-induced expression of brain-derived neurotrophic factor is disrupted in the brainstem of methyl-CpG-binding protein 2 null mice

Nerve growth factor and transforming growth factor-β serum levels in acute stroke patients

Oxidative stress in obstructive sleep apnea and intermittent hypoxia-revisited -the bad ugly and good: implications to the heart and brain

Oxidative stress, inflammation, and cancer: how are they linked?

Obstructive sleep apnea syndrome and inflammation

Molecular signatures of obstructive sleep apnea in adults: a review and perspective

Effects of obstructive sleep apnea on serum brain-derived neurotrophic factor protein, cortisol, and lipid levels

Changes of serum brain-derived neurotrophic factor in children with obstructive sleep apnoeahypopnoea syndrome following adenotonsillectomy

Regulation of brain-derived neurotrophic factor (BDNF) during sleep apnoea treatment

BDNF and synaptic plasticity, cognitive function, and dysfunction. Lewin G, Carter B, Neurotrophic Factors

The evaluation of serum brain-derived neurotrophic factor and neurofilament light chain levels in patients with obstructive sleep apnea syndrome

The authors have no conflicts of interest to declare.

Burak Arslan analyzed the data, contributed to the design of the current study, and wrote the manuscript. Rabia Şemsi analyzed the data and wrote the manuscript. Aylin Sepici Dinçel analyzed the data and drafted the manuscript. Ayşe _ Iriz designed the cohort collection and drafted the manuscript.

https://orcid.org/0000-0001-7229-3226 BIBLIOGRAPHY